hematopoietic stem cells

[Cell Death Discovery] Researchers performed high-throughput screening and identified that oridonin, an ent-kaurene diterpenoid extracted from the Chinese herb Rabdosia rubescens, inhibited DNMT3A R882 mutant leukemic cells at a low-micromolar concentration.

[Nature Communications] Investigators reported that TET2 mutations are associated with DNA hypermethylation at enhancer sites in whole blood in clonal hematopoiesis of indeterminate potential and in both granulocytes and mononuclear cells in clonal cytopenia of undetermined significance.

[Bone Marrow Transplantation] Investigators provide an overview of the cellular therapies available for the management of systemic sclerosis, including systemically injected therapies and locally administered regenerative cell therapies.

[Cytotherapy] The authors compared the capacity of four dimethyl sulfoxide (DMSO)-free freezing media to cryopreserve cord blood HSCs: CryoProtectPureSTEM, CryoScarless, CryoNovo P24 and Pentaisomaltose. Clinical-grade DMSO/dextran solution was used as control.

[Blood Advances] The authors employed HSCs, multipotent progenitor cells, common myeloid progenitor cells, megakaryocyte-erythroid progenitor cells, and erythroblasts from human cord blood as an erythroid differentiation model to explore the coordinated regulatory functions of lncRNAs and chromatin accessibility by integrating RNA-Seq and ATAC-Seq data.

[Blood Advances] 43 patients received hematopoietic stem cell transplantation (HSCT) in first remission including 38 patients receiving protocol-specified HSCT with conditioning consisting of individualized targeted doses of busulfan, etoposide, and cyclophosphamide. Three-year event-free survival of 56.8% and overall survival of 80.2% were accomplished.